Allogene Therapeutics, Inc. Right-of-Use Asset Obtained in Exchange for Operating Lease Liability
Allogene Therapeutics, Inc. (ALLO) reported Right-of-Use Asset Obtained in Exchange for Operating Lease Liability of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-12.
Financial Statements › Notes › Leases
us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability · last filed 2026-03-12
- Allogene Therapeutics, Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2025-12-31 was $0.00.
- Allogene Therapeutics, Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2025-09-30 was $0.00.
- Allogene Therapeutics, Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2025-06-30 was $0.00.
- Allogene Therapeutics, Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2025-03-31 was $0.00, a 100.00% decline year-over-year.
- Allogene Therapeutics, Inc. right-of-use asset obtained in exchange for operating lease liability for fiscal 2025 was $0.00, a 100.00% decline from fiscal 2024.
- Allogene Therapeutics, Inc. right-of-use asset obtained in exchange for operating lease liability for fiscal 2024 was $2.41M.
- Allogene Therapeutics, Inc. right-of-use asset obtained in exchange for operating lease liability for fiscal 2023 was $0.00, a 100.00% decline from fiscal 2022.
- Allogene Therapeutics, Inc. right-of-use asset obtained in exchange for operating lease liability for fiscal 2022 was $31.36M, a 56.19% increase from fiscal 2021.
| Period end | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 1 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 3 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 6 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 9 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 12 month |
|---|---|---|---|---|---|
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $0.00 derived: sum of 2 quarters · filed 2026-03-12 | $0.00 derived: sum of 3 quarters · filed 2026-03-12 | $0.00 10-K · filed 2026-03-12 | |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $0.00 derived: sum of 2 quarters · filed 2025-11-06 | $0.00 10-Q · filed 2025-11-06 | $0.00 derived: sum of 4 quarters · filed 2026-03-12 | |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | $0.00 10-Q · filed 2025-08-13 | $0.00 derived: sum of 3 quarters · filed 2026-03-12 | $0.00 derived: sum of 4 quarters · filed 2026-03-12 | |
| 2025-03-31 | $0.00 10-Q · filed 2025-05-13 | $0.00 derived: sum of 2 quarters · filed 2026-03-12 | $0.00 derived: sum of 3 quarters · filed 2026-03-12 | $0.00 derived: sum of 4 quarters · filed 2026-03-12 | |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $0.00 derived: sum of 2 quarters · filed 2026-03-12 | $0.00 derived: sum of 3 quarters · filed 2026-03-12 | $2.41M 10-K · filed 2026-03-12 | |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $0.00 derived: sum of 2 quarters · filed 2025-11-06 | $2.41M 10-Q · filed 2025-11-06 | $2.41M derived: sum of 4 quarters · filed 2025-11-06 | |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | $2.41M 10-Q · filed 2025-08-13 | $2.41M derived: sum of 3 quarters · filed 2025-08-13 | $2.41M derived: sum of 4 quarters · filed 2025-08-13 | |
| 2024-03-31 | $2.41M 10-Q · filed 2025-05-13 | $2.41M derived: sum of 2 quarters · filed 2025-05-13 | $2.41M derived: sum of 3 quarters · filed 2025-05-13 | $2.41M derived: sum of 4 quarters · filed 2025-05-13 | |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | $0.00 derived: sum of 2 quarters · filed 2025-03-13 | $0.00 derived: sum of 3 quarters · filed 2025-03-13 | $0.00 10-K · filed 2025-03-13 | |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $0.00 derived: sum of 2 quarters · filed 2024-11-07 | $0.00 10-Q · filed 2024-11-07 | $0.00 derived: sum of 4 quarters · filed 2024-11-07 | |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | $0.00 10-Q · filed 2024-08-07 | $0.00 derived: sum of 3 quarters · filed 2024-08-07 | $0.00 derived: sum of 4 quarters · filed 2024-08-07 | |
| 2023-03-31 | $0.00 10-Q · filed 2024-05-13 | $0.00 derived: sum of 2 quarters · filed 2024-05-13 | $0.00 derived: sum of 3 quarters · filed 2024-05-13 | ||
| 2022-12-31 | $0.00 derived: 10-K/A 12 month − 10-Q 9 month · filed 2024-03-14 | $0.00 derived: sum of 2 quarters · filed 2024-03-14 | $31.36M 10-K/A · filed 2024-03-14 | ||
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | $31.36M 10-Q · filed 2023-11-02 | |||
| 2022-06-30 | $31.36M 10-Q · filed 2023-08-02 | ||||
| 2021-12-31 | $20.08M derived: 10-K/A 12 month − 10-Q 9 month · filed 2024-03-14 | $20.08M derived: sum of 2 quarters · filed 2024-03-14 | $20.08M 10-K/A · filed 2024-03-14 | ||
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-02 | $0.00 10-Q · filed 2022-11-02 | |||
| 2021-06-30 | $0.00 10-Q · filed 2022-08-09 | ||||
| 2020-12-31 | $0.00 10-K/A · filed 2024-03-14 | ||||
| 2019-12-31 | $13.83M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-23 | $13.83M 10-K · filed 2022-02-23 | |||
| 2019-09-30 | $0.00 10-Q · filed 2019-11-05 | ||||
| 2018-12-31 | $7.69M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $33.02M 10-K · filed 2021-02-25 | |||
| 2018-09-30 | $25.32M 10-Q · filed 2019-11-05 | ||||
| 2017-12-31 | $0.00 10-K · filed 2020-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |